NCT06543823 SUPRATHEL 250 as a Treatment for Oropharyngeal Wounds
| NCT ID | NCT06543823 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Alaa Emara |
| Condition | Tonsillitis |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2025-04-30 |
| Primary Completion | 2026-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2025-04-30 with a primary completion date of 2026-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To assess the use of Suprathel 250 for mucosal reconstruction in oropharyngeal defects. The membrane will be applied after tonsillectomy procedures and compared to bare wounds' healing
Eligibility Criteria
* Indication for tonsillectomy according to the applicable clinical guideline. * Male or female patients aged 18 years or older. * Ability to understand the study information and provide written informed consent.
Contact & Investigator
Alaa Emara
PRINCIPAL INVESTIGATOR
Cairo University
Frequently Asked Questions
Who can join the NCT06543823 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Tonsillitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06543823 currently recruiting?
Yes, NCT06543823 is actively recruiting participants. Contact the research team at alaa.emara@polymedics.com for enrollment information.
Where is the NCT06543823 trial being conducted?
This trial is being conducted at Stuttgart, Germany.
Who is sponsoring the NCT06543823 clinical trial?
NCT06543823 is sponsored by Alaa Emara. The principal investigator is Alaa Emara at Cairo University. The trial plans to enroll 80 participants.